Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 1:153:111497.
doi: 10.1016/j.exger.2021.111497. Epub 2021 Jul 26.

Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults

Elizabeth Hernández Ramos  1 , Vianed Marsán Suárez  2 , Imilla Casado Hernández  3 , Rinaldo Puga Gomez  4 , Dagmar García Rivera  5 , Mary Carmen Reyes Zamora  6 , Arturo Chang Monteagudo  7 , Yenisey Triana Marrero  8 , Gabriela Díaz Domínguez  9 , Yaneisy Duarte Pérez  10 , Consuelo Macías Abraham  11 , Ana María Simón Pita  12
Affiliations

Effect of Biomodulina-T® and VA-MENGOC-BC® on lymphocyte subpopulations in older adults

Elizabeth Hernández Ramos et al. Exp Gerontol. .

Abstract

Introduction: The elderly population suffers from the natural process called immunosenescence, which may be related to the high mortality rates it has against the SARS-CoV2 virus, which is why therapies that improve the immune status are required. The combined treatment of the VA-MENGOC-BC® (V-BC) vaccine and the Biomodulina T® (BT) drug could achieve this purpose. This treatment could immunomodulate both the innate and adaptive branches of the immune system simultaneously.

Objective: To determine the effect of BT and V-BC on the immunomodulation of lymphocyte subpopulations in older adults.

Methods: Our study was carried out in 30 apparently healthy Cuban adults over 65 years of age. The study included three groups of 10 subjects per treatment: a combination of both and the monotherapies. Before and 7 days after treatment, 2 mL of peripheral blood was drawn from each subject. Multiparametric flow cytometry was used to identify lymphocyte subpopulations. For the comparison between the groups, point estimates and the confidence intervals of the Odds Ratio were made.

Results: We found that subpopulations of B lymphocytes and natural cytotoxic T (NKT) cells increased only with the administration of BT. Additionally, combination treatments and V-BC did not generate statistically significant immunomodulatory changes in any of the studied lymphocyte subpopulations.

Conclusions: BT presented an immunoenhancing effect on the B and NKT lymphocyte subpopulations of older adults. The three-dose treatment scheme a novel and specific treatment strategy for this formulation. We also were verified that the combined application of V-BC and BT did not have the expected benefits. All these findings suggest that BT administration is a promising approach for immune restoration and to offering protection in elderly patients against COVID-19.

Keywords: Biomodulina T; Flow cytometry; Immunosenescence; Lymphocytes; VA-MENGOC-BC.

PubMed Disclaimer

Conflict of interest statement

The author, participating institutions and researchers declare no conflict of interest. In this study, all the ethical principles typical of human research were applied. The identity of the study participants was kept anonymous to maintain their privacy.

Figures

Figs. 1 and 2
Figs. 1 and 2
Analysis strategy of B lymphocytes, before and after treatment with Biomodulina T, respectively. A: Discrimination of singlets events from FSC. B: Separation of lymphocytes using dotplot SSC/CD45FITC. C: Discrimination by CD19+ antigen from SSC.
Figs. 3 and 4
Figs. 3 and 4
Analysis strategy of natural cytotoxic T cells (NKT) before and after treatment with Biomodulina T, respectively. A: Discrimination of singlets events from FSC. B: Separation of lymphocytes using dotplot SSC/CD45FITC. C: Discrimination by CD3+ antigen of T lymphocytes from SSC (Figs. 1 and 2). D: Selection by CD56+ antigen from SSC (Figs. 3 and 4).
See this image and copyright information in PMC

References

    1. Abo T., Kawamura T., Watanabe H. Physiological responses of extrathymic T cells in the liver. Immunol. Rev. 2000;174:135–149. doi: 10.1034/j.1600-0528.2002.017415.x. - DOI - PubMed
    1. Arango Prado Md.C., Villegas Valverde C.A., Soto Pardeiro P., Torres López G., Morales A.M., Faxas García M.E. Caracterización de los inmunofenotipos linfocitarios de sangre periférica en pacientes con cáncer. Rev. Cuba. Hematol. Inmunol. Hemoter. 2020;36(2):16–21.
    1. Bae E.A., Seo H., Kim I.K., Jeon I., Kang C.Y. Roles of NKT cells in cancer immunotherapy. Arch. Pharm. Res. 2019;42(7):543–548. doi: 10.1007/s12272-019-01139-8. - DOI - PubMed
    1. Crooke S.N., Ovsyannikova I.G., Poland G.A., Kennedy R.B. Immunosenescence and human vaccine immune responses. Immun. Ageing. 2019;16:25. doi: 10.1186/s12979-019-0164-9. - DOI - PMC - PubMed
    1. Emoto M., Kaufmann S.H.E. Liver NKT cells: an account of heterogeneity. Trends Immunol. 2003;24(7):364–369. doi: 10.1016/s1471-4906(03)00162-5. - DOI - PubMed